Press release
Change in number of shares and votes in Oncopeptides AB (publ)
During April, the number of shares and votes in Oncopeptides AB (publ) (”Oncopeptides” or the ”Company”) has increased by 977 906 shares and votes due to the new issue of shares that was made in connection with the exercise of the over-allotment option, subsequent to the listing of the Company’s shares on Nasdaq Stockholm. As of April 28, 2017, the number of shares and votes in Oncopeptides amounts to 39,806,021.
About Oncopeptides
Oncopeptides is a research and development stage pharmaceutical company developing drugs for the treatment of cancer. Since the founding of the company the focus has primarily been on the development of the lead product candidate Ygalo, an innovative, peptidase-potentiated alkylator intended for effective and focused treatment of hematological cancers, and in particular multiple myeloma. Ygalo is intended to demonstrate better results from treatment compared to established alternative drugs in the treatment of patients with multiple myeloma. Ygalo could potentially provide physicians with a new treatment option for patients suffering from this serious disease.
Visit www.oncopeptides.se for more information.
For further information, please contact:
Jakob Lindberg, CEO at Oncopeptides
E-mail: jakob.lindberg@oncopeptides.se
Rein Piir, Head of Investor Relations at Oncopeptides
E-mail: rein.piir@oncopeptides.se
This information is such that Oncopeptides is required to publish under the Swedish Financial Instruments Trading Act. The information was released for public disclosure, through the agency of the contact person above, on April 28, 2017 at 6.00 p.m. (CET).